ARVOIVD

Decades of clinical immunoproteomics and technical platform research resulted in the development of FastMDD TM, our core technology platform based on antibody microarray analysis. FastMDD TM is dedicated to the early diagnosis of MDD, to predicting disease progression and to monitoring the therapeutic responsiveness. The platform technology can also be used as a clinical trial diagnostic surrogate endpoint tool through Arvo's clinical staging scanning FastMDD TM CSS (Clinical Staging Survey).

Also known as: Arvo Gruppe S.r.l., Arvo PC

Primary location: Thessaloniki Greece